Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,835,706
  • Shares Outstanding, K 136,547
  • Annual Sales, $ 1,697 M
  • Annual Income, $ -190,430 K
  • EBIT $ -227 M
  • EBITDA $ -196 M
  • 60-Month Beta 1.79
  • Price/Sales 12.02
  • Price/Cash Flow N/A
  • Price/Book 16.29

Options Overview Details

View History
  • Implied Volatility 38.26% ( -0.42%)
  • Historical Volatility 59.40%
  • IV Percentile 3%
  • IV Rank 3.90%
  • IV High 110.15% on 08/02/24
  • IV Low 35.34% on 05/21/24
  • Put/Call Vol Ratio 0.48
  • Today's Volume 345
  • Volume Avg (30-Day) 1,321
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 7,083
  • Open Int (30-Day) 16,968

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.60
  • Number of Estimates 6
  • High Estimate -0.49
  • Low Estimate -0.71
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.85 +8.63%
on 04/21/25
166.00 -7.83%
on 05/09/25
+4.93 (+3.33%)
since 04/17/25
3-Month
125.38 +22.03%
on 04/07/25
173.90 -12.02%
on 02/20/25
-19.60 (-11.36%)
since 02/19/25
52-Week
92.14 +66.06%
on 08/05/24
183.00 -16.39%
on 01/13/25
+46.55 (+43.72%)
since 05/17/24

Most Recent Stories

More News
Natera: Q1 Earnings Snapshot

Natera: Q1 Earnings Snapshot

NTRA : 153.28 (+0.45%)
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

NTRA : 153.28 (+0.45%)
AMPH : 24.73 (-0.52%)
CLOV : 3.61 (+1.69%)
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

NTRA : 153.28 (+0.45%)
AMPH : 24.73 (-0.52%)
CLOV : 3.61 (+1.69%)
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

NTRA : 153.28 (+0.45%)
EXAS : 56.72 (+0.53%)
INCY : 63.39 (+0.13%)
REGN : 593.87 (-0.08%)
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

NTRA : 153.28 (+0.45%)
EXAS : 56.72 (+0.53%)
INCY : 63.39 (+0.13%)
REGN : 593.87 (-0.08%)
3 Reasons NTRA Has Explosive Upside Potential

3 Reasons NTRA Has Explosive Upside Potential

NTRA : 153.28 (+0.45%)
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks

Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual...

NTRA : 153.28 (+0.45%)
COHR : 79.04 (+0.56%)
CPNG : 27.16 (-0.29%)
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

NTRA : 153.28 (+0.45%)
EXAS : 56.72 (+0.53%)
INCY : 63.39 (+0.13%)
REGN : 593.87 (-0.08%)
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

NTRA : 153.28 (+0.45%)
EXAS : 56.72 (+0.53%)
INCY : 63.39 (+0.13%)
REGN : 593.87 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

3rd Resistance Point 158.54
2nd Resistance Point 155.97
1st Resistance Point 154.28
Last Price 153.28
1st Support Level 150.02
2nd Support Level 147.45
3rd Support Level 145.76

See More

52-Week High 183.00
Last Price 153.28
Fibonacci 61.8% 148.29
Fibonacci 50% 137.57
Fibonacci 38.2% 126.85
52-Week Low 92.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »